Eastern equine encephalitis virus-vaccinated mice are protected against Madariaga virus despite negligible neutralizing antibody titers
- 1Texas A&M University
Abstract
Madariaga virus (MADV) is an understudied member of the eastern equine encephalitis virus (EEEV) complex that circulates widely in Latin America and may be geographically expanding. Spillover infections can cause severe disease in humans and equids. Despite these public and animal health concerns, no MADV vaccines or treatments are available. In this context, commercially available equine vaccines against the closely related North American EEEV (NA EEEV) could potentially provide heterologous protection against MADV. However, previous studies have shown weak or undetectable MADV-neutralizing antibody responses in equids and humans immunized with inactivated NA EEEV vaccines, and whether protection can occur despite these limited neutralizing antibody responses remains unknown. We evaluated a commercial equine trivalent inactivated NA EEEV vaccine against MADV challenge in NIH Swiss mice. Animals received two vaccine doses 14 days apart and were challenged 14 days later. Vaccination provided protection against lethal disease, whereas 36% mortality occurred in the unvaccinated group. Overall, vaccinated animals developed fewer and less severe clinical signs. MADV RNAemia was not detected following vaccination, and tissue dissemination was significantly reduced compared with the unvaccinated group. Central nervous system lesions were observed only in the unvaccinated group. Despite protection, most vaccinated mice had no detectable MADV-neutralizing antibody titers, and those that seroconverted developed only low titers, whereas most unvaccinated mice developed intermediate to high titers. These findings demonstrate that an inactivated NA EEEV-containing vaccine can protect against severe MADV disease despite limited MADV-neutralizing antibody responses.
Related
- Transmission potential of Culex and Aedes species for Madariaga virus, a member of the eastern equine encephalitis virus complex
- Single-cell-resolved dynamic immune remodeling following Omicron infection and recovery in vaccinated individuals
- Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual
- Fulminant serogroup B meningococcemia in an adolescent vaccinated against serogroups A and C: highlighting the serogroup B vaccination gap in China-a case report and literature review.
- HLA allele DRB1*01:03: the genetic link to neutralizing IL-10 antibodies in inflammatory bowel disease
BibTeX
@misc{cerezo2026eastern,
title = {{Eastern equine encephalitis virus-vaccinated mice are protected against Madariaga virus despite negligible neutralizing antibody titers}},
author = {S. Cerezo and C.-H. Sung and W. Tang and G. L. Hamer and R. Rech and t. magalhaes},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.14.751423},
url = {https://www.biorxiv.org/content/10.64898/2026.09.14.751423v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Eastern equine encephalitis virus-vaccinated mice are protected against Madariaga virus despite negligible neutralizing antibody titers
AU - S. Cerezo
AU - C.-H. Sung
AU - W. Tang
AU - G. L. Hamer
AU - R. Rech
AU - t. magalhaes
PY - 2026
DA - 2026/09/14
PB - bioRxiv
DO - 10.64898/2026.09.14.751423
UR - https://www.biorxiv.org/content/10.64898/2026.09.14.751423v1
AB - Madariaga virus (MADV) is an understudied member of the eastern equine encephalitis virus (EEEV) complex that circulates widely in Latin America and may be geographically expanding. Spillover infections can cause severe disease in humans and equids. Despite these public and animal health concerns, no MADV vaccines or treatments are available. In this context, commercially available equine vaccines against the closely related North American EEEV (NA EEEV) could potentially provide heterologous protection against MADV. However, previous studies have shown weak or undetectable MADV-neutralizing antibody responses in equids and humans immunized with inactivated NA EEEV vaccines, and whether protection can occur despite these limited neutralizing antibody responses remains unknown. We evaluated a commercial equine trivalent inactivated NA EEEV vaccine against MADV challenge in NIH Swiss mice. Animals received two vaccine doses 14 days apart and were challenged 14 days later. Vaccination provided protection against lethal disease, whereas 36% mortality occurred in the unvaccinated group. Overall, vaccinated animals developed fewer and less severe clinical signs. MADV RNAemia was not detected following vaccination, and tissue dissemination was significantly reduced compared with the unvaccinated group. Central nervous system lesions were observed only in the unvaccinated group. Despite protection, most vaccinated mice had no detectable MADV-neutralizing antibody titers, and those that seroconverted developed only low titers, whereas most unvaccinated mice developed intermediate to high titers. These findings demonstrate that an inactivated NA EEEV-containing vaccine can protect against severe MADV disease despite limited MADV-neutralizing antibody responses.
ER -